Kiyoaki Sakata

1.3k citations

19 papers · 865 indexed · h-index 14

Co-authors: Toshihiko Fujii Yuko Aoki Hirosato Ebiike Miyako Masubuchi Satoshi Sogabe Nobuo Shimma Yasuhiko Shiratori Ken‐ichi Kawasaki
Topics: Cancer therapeutics and mechanisms (5 papers)Synthesis and biological activity (4 papers)Fibroblast Growth Factor Research (4 papers)
Cited by: Organic Chemistry Toxicology Molecular Biology
Journals: Cancer Research Scientific Reports Clinical Cancer Research
Partner nations: United States Japan Switzerland

In The Last Decade

Kiyoaki Sakata

19 papers receiving 813 citations

Peers

Countries citing papers authored by Kiyoaki Sakata

Since Specialization

Citations

This map shows the geographic impact of Kiyoaki Sakata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiyoaki Sakata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiyoaki Sakata more than expected).

Fields of papers citing papers by Kiyoaki Sakata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiyoaki Sakata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiyoaki Sakata. The network helps show where Kiyoaki Sakata may publish in the future.

Co-authorship network of co-authors of Kiyoaki Sakata

This figure shows the co-authorship network connecting the top 25 collaborators of Kiyoaki Sakata. A scholar is included among the top collaborators of Kiyoaki Sakata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiyoaki Sakata. Kiyoaki Sakata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial 2022 ·Scientific Reports ·Shunichiro Komatsu,Yoko Kayukawa,Yoko Miyazaki,Akihisa Kaneko,(unknown),Takahiro Ishiguro,(unknown),Werner Frings,(unknown),Kiyoaki Sakata,Toshihiko Fujii,Shohei Kishishita,Takehisa Kitazawa,Mika Endo,Yuji Sano	10
2	Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer 2018 ·Molecular Cancer Therapeutics ·Hiroshi Tanaka,Hitoshi Sase,Toshiyuki Tsukaguchi,Masami Hasegawa,Hiromi Tanimura,Miyuki Yoshida,Kiyoaki Sakata,Toshihiko Fujii,Yukako Tachibana,Kenji Takanashi,Atsuko Higashida,Kiyoshi Hasegawa,Yoshiyuki Ono,Nobuhiro Oikawa,Toshiyuki Mio	17
3	Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2 -Amplified Gastric Cancer 2018 ·Molecular Cancer Therapeutics ·Hitoshi Sase,Yoshito Nakanishi,Satoshi Aida,(unknown),(unknown),Toshihiko Fujii,Kiyoaki Sakata,Toshiyuki Mio,Masahiro Aoki,Nobuya Ishii	17
4	MITF suppression by CH5552074 inhibits cell growth in melanoma cells 2017 ·Cancer Chemotherapy and Pharmacology ·Satoshi Aida,(unknown),(unknown),Kiyoaki Sakata,Toshihiko Fujii,Hiroshi Sakamoto,Takakazu Mizuno	9
5	ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor 2015 ·Molecular Cancer Therapeutics ·Yoshito Nakanishi,Hideaki Mizuno,Hitoshi Sase,Toshihiko Fujii,Kiyoaki Sakata,(unknown),Yuko Aoki,Masahiro Aoki,Nobuya Ishii	24
6	Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression 2014 ·Molecular Cancer Therapeutics ·Yuji Sano,Eri Hashimoto,Noriaki Nakatani,(unknown),Yasuko Satoh,Kiyoaki Sakata,Toshihiko Fujii,Kaori Fujimoto-Ouchi,Masamichi Sugimoto,Shigehisa Nagahashi,Masahiro Aoki,(unknown),Eiichi Sasaki,Yasushi Yatabe	22
7	The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor 2014 ·Molecular Cancer Therapeutics ·Yoshito Nakanishi,(unknown),Toshiyuki Tsukaguchi,Toshihiko Fujii,Kiyoaki Sakata,Hitoshi Sase,(unknown),Kenji Morikami,Hidetoshi Shindoh,Toshiyuki Mio,Hirosato Ebiike,Naoki Taka,Yuko Aoki,Nobuya Ishii	101
8	Abstract 2729: FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel chemical scaffold 2014 ·Cancer Research ·Yoshito Nakanishi,(unknown),Toshiyuki Tsukaguchi,(unknown),Toshihiko Fujii,Kiyoaki Sakata,Hitoshi Sase,(unknown),Yasuko Sato,Kenji Morikami,Hidetoshi Shindoh,Toshiyuki Mio,Hirosato Ebiike,Naoki Taka,Yuko Aoki,Nobuya Ishii	1
9	Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non‐small‐cell lung cancer 2013 ·Cancer Science ·Naomi Ono,Toshikazu Yamazaki,Toshiyuki Tsukaguchi,Toshihiko Fujii,Kiyoaki Sakata,Atsushi Suda,Takuo Tsukuda,Toshiyuki Mio,Nobuya Ishii,Osamu Kondoh,Yuko Aoki	26
10	Abstract 2728: Onartuzumab (MetMAb) restores sensitivity to erlotinib in EGFR mutant NSCLC cells expressing HGF 2012 ·Cancer Research ·Yuji Sano,Eri Hashimoto,Noriaki Nakatani,Kaori Fujimoto-Ouchi,Nobuya Ishii,Yasuko Satoh,Kiyoaki Sakata,Toshihiko Fujii,Shigehisa Nagahashi,Yuko Aoki,Masahiro Aoki	2
11	The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations 2011 ·Clinical Cancer Research ·Hiroshi Tanaka,Miyuki Yoshida,Hiromi Tanimura,Toshihiko Fujii,Kiyoaki Sakata,Yukako Tachibana,Jun Ohwada,Hirosato Ebiike,Shino Kuramoto,Keiichi Morita,Yasushi Yoshimura,Toshikazu Yamazaki,Nobuya Ishii,Osamu Kondoh,Yuko Aoki	79
12	Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)‐overexpressing cancers 2011 ·Cancer Science ·Naomi Ono,Toshikazu Yamazaki,Yoshito Nakanishi,Toshihiko Fujii,Kiyoaki Sakata,Yukako Tachibana,Atsushi Suda,(unknown),Takaaki Miura,Shigeo Sato,Ryoichi Saitoh,(unknown),Takuo Tsukuda,Toshiyuki Mio,Nobuya Ishii,Osamu Kondoh,Yuko Aoki	21
13	Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance 2007 ·Cancer Genetics and Cytogenetics ·Nami Yabuki,Kiyoaki Sakata,Tomoaki Yamasaki,Hiromichi Terashima,Toshiyuki Mio,(unknown),Toshihiko Fujii,Kunio Kitada	58
14	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 3 2003 ·Bioorganic & Medicinal Chemistry Letters ·Ken‐ichi Kawasaki,Miyako Masubuchi,Kenji Morikami,Satoshi Sogabe,(unknown),Hirosato Ebiike,Satoshi Niizuma,(unknown),Toshihiko Fujii,Kiyoaki Sakata,Hidetoshi Shindoh,Yasuhiko Shiratori,Yuko Aoki,Tatsuo Ohtsuka,Nobuo Shimma	90
15	Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase 2003 ·Bioorganic & Medicinal Chemistry ·Miyako Masubuchi,Hirosato Ebiike,Ken‐ichi Kawasaki,Satoshi Sogabe,Kenji Morikami,Yasuhiko Shiratori,Shinji Tsujii,Toshihiko Fujii,Kiyoaki Sakata,(unknown),Hidetoshi Shindoh,Yuko Aoki,Tatsuo Ohtsuka,Nobuo Shimma	106
16	Crystal Structures of Candida albicans N-Myristoyltransferase with Two Distinct Inhibitors 2002 ·Chemistry & Biology ·Satoshi Sogabe,Miyako Masubuchi,Kiyoaki Sakata,Takaaki A. Fukami,Kenji Morikami,Yasuhiko Shiratori,Hirosato Ebiike,Ken‐ichi Kawasaki,Yuko Aoki,Nobuo Shimma,A. D’Arcy,Fritz K. Winkler,David W. Banner,Tatsuo Ohtsuka	107
17	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 2 2002 ·Bioorganic & Medicinal Chemistry Letters ·Hirosato Ebiike,Miyako Masubuchi,Pingli Liu,Ken‐ichi Kawasaki,Kenji Morikami,Satoshi Sogabe,(unknown),Toshihiko Fujii,Kiyoaki Sakata,Hidetoshi Shindoh,Yasuhiko Shiratori,Yuko Aoki,Tatsuo Ohtsuka,Nobuo Shimma	66
18	Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N -myristoyltransferase. Part 1 2001 ·Bioorganic & Medicinal Chemistry Letters ·Miyako Masubuchi,Ken‐ichi Kawasaki,Hirosato Ebiike,Yoshihiko Ikeda,Shinji Tsujii,Satoshi Sogabe,Toshihiko Fujii,Kiyoaki Sakata,Yasuhiko Shiratori,Yuko Aoki,Tatsuo Ohtsuka,Nobuo Shimma	103
19	Protein‐bound conformation of a specific inhibitor against Candida albicans myristoyl‐CoA:protein N‐myristoyltransferase in the ternary complex with CaNmt and myristoyl‐CoA by transferred NOE measurements 2001 ·European Journal of Biochemistry ·Takaaki Miura,Werner Klaus,Alfred Ross,Kiyoaki Sakata,Miyako Masubuchi,Hans Senn	6

About Kiyoaki Sakata

Kiyoaki Sakata is a scholar working on Organic Chemistry, Molecular Biology and Infectious Diseases, having authored 19 papers that have together received 865 indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (5 papers), Synthesis and biological activity (4 papers) and Fibroblast Growth Factor Research (4 papers). The work is most often cited by research in Organic Chemistry (320 citations), Toxicology (30 citations) and Molecular Biology (476 citations). Kiyoaki Sakata has collaborated with scholars based in United States, Japan and Switzerland. Frequent co-authors include Toshihiko Fujii, Yuko Aoki, Hirosato Ebiike, Miyako Masubuchi, Satoshi Sogabe, Nobuo Shimma, Yasuhiko Shiratori, Ken‐ichi Kawasaki, Tatsuo Ohtsuka and Kenji Morikami. Their work appears in journals such as Cancer Research, Scientific Reports and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact